Teva gets a badly needed win: FDA OKs their runner-up CGRP migraine drug, with Eli Lilly trailing behind
The FDA has come through with a delayed OK for Teva’s new migraine drug. And this one represents a badly needed win for the new …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
